Background: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease in which fibroblast-like synoviocytes (FLS) play a critical role in its pathogenesis. Due to the significant side effects associated with conventional treatments and the lack of response to the therapy in some patients, researchers are investigating novel therapeutic approaches that offer improved efficacy and a more favorable safety profile. This study aimed to investigate the cytotoxic activity of dimethylamino parthenolide (DMAPT) on the rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) cell line.
Methods: For this purpose, the RA-FLS cell line, previously generated in our unpublished studies, was treated with varying concentrations of DMAPT (0-160 μM) for 24 and 48 hours. Cell viability was assessed using the MTT assay. The half-maximal inhibitory concentration (IC₅₀) values were derived from dose-response curves fitted using GraphPad Prism software (version).
Results: Our results demonstrated that DMAPT exerts cytotoxic effects on the RA-FLS cell line, leading to a significant reduction in cell viability. This cytotoxic effect is dose-dependent, such that cell viability decreased with increasing dose. The half-maximal inhibitory concentration (IC ₅₀) values of DMAPT for rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) were 51.02 μM at 24 hours and 45.8 μM at 48 hours.
Conclusion: Our results demonstrated that DMAPT exerts cytotoxic effects on rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS).